ClinicalTrials.gg
CompletedNCT02919579DriveSaFe2Updated Apr 27, 2025

A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder

A Phase 1 interventional study of Placebo (Intranasal) and Esketamine in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Netherlands. Open to participants aged 22 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
22 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing esketamine in Depressive Disorder, Major — 5 open to participants now, 5 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Major.

Enrollment
14th of 17
27 · median 147
Started
2016
the only one that year
Phase 1
2 of 17
1 open now
Registered
3rd of 17
by date
Lead sponsor
7 of 17
Janssen Research & Development, LLC

Among the 17 studies testing esketamine in Depressive Disorder, Major, this one is the 14th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 1, and was the 3rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 17 studies testing esketamine in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 22 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing esketamine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the effect of a single 84-milligram (mg) dose of intranasal esketamine compared to placebo, on next day driving performance and repeated administration of 84 mg intranasal esketamine on same-day driving performance as assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test.

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
22 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to adhere to the prohibitions and restrictions specified in this protocol
  • If a woman, must have a negative serum beta human chorionic gonadotropin pregnancy test at screening and a negative urine pregnancy test on Day 1 of Period 1 in Part A and prior to study drug administration in Part B
  • Comfortable with self-administration of intranasal medication and able to follow instructions provided
  • Normal visual acuity (corrected or uncorrected)
  • Based on self-report, able to consume an amount of alcohol that typically produces a blood alcohol concentration (BAC) of 0.05 percent (that is, 2 to 3 alcoholic drinks ingested within 2 hours on a single occasion)

Exclusion criteria

Exclusion Criteria:

  • Current or prior diagnosis of psychosis/psychotic or bipolar disorder
  • Primary sleep disorder, such as insomnia, requiring pharmacological intervention at Screening
  • abnormal values for hematology, clinical chemistry, or urinalysis at screening or Day 1 of Period 1 as deemed appropriate by the investigator
  • Clinically significant abnormal physical examination, vital signs, or 12-lead (ECG) at screening or Day 1 of Period 1 as deemed appropriate by the investigator
  • History of moderate or severe use disorder according to (DSM-IV or DSM-5) criteria within 1 year before screening or positive test result(s) for alcohol and/or drugs of abuse (such as barbiturates, opiates, cocaine, cannabinoids, amphetamines, and benzodiazepines) at screening and Day 1 of Period 1
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Part A: Sequence ABC (Placebo+Alcohol+Esketamine)

    Participants will receive intranasal placebo on Day 1 and oral placebo on Day 2 \[Treatment A\] in Period 1, then intranasal placebo on Day 1 and Oral alcohol on Day 2 \[Treatment B\] in Period 2, followed by intranasal esketamine on Day 1 and oral placebo on Day 2 \[Treatment C\] in Period 3.

    Drug: Placebo (Intranasal) · Drug: Esketamine · Other: Alcohol · Drug: Placebo (Oral)

  • Experimental
    Part A: Sequence BCA (Placebo+Alcohol+Esketamine)

    Participants will receive Treatment B in Period 1, then Treatment C in Period 2, followed by Treatment A in Period 3.

    Drug: Placebo (Intranasal) · Drug: Esketamine · Other: Alcohol · Drug: Placebo (Oral)

  • Experimental
    Part A: Sequence CAB (Placebo+Alcohol+Esketamine)

    Participants will receive Treatment C in Period 1, then Treatment A in Period 2, followed by Treatment B in Period 3.

    Drug: Placebo (Intranasal) · Drug: Esketamine · Other: Alcohol · Drug: Placebo (Oral)

  • Experimental
    Part A: Sequence CBA (Placebo+Alcohol+Esketamine)

    Participants will receive Treatment C in Period 1, then Treatment B in Period 2, followed by Treatment A in Period 3.

    Drug: Placebo (Intranasal) · Drug: Esketamine · Other: Alcohol · Drug: Placebo (Oral)

  • Experimental
    Part A: Sequence ACB (Placebo+Alcohol+Esketamine)

    Participants will receive Treatment A in Period 1, then Treatment C in Period 2, followed by Treatment B in Period 3.

    Drug: Placebo (Intranasal) · Drug: Esketamine · Other: Alcohol · Drug: Placebo (Oral)

  • Experimental
    Part A: Sequence BAC (Placebo+Alcohol+Esketamine)

    Participants will receive Treatment B in Period 1, then Treatment A in Period 2, followed by Treatment C in Period 3.

    Drug: Placebo (Intranasal) · Drug: Esketamine · Other: Alcohol · Drug: Placebo (Oral)

  • Experimental
    Part B: Placebo+Esketamine

    Participants will receive intranasal placebo on Day 1, followed by intranasal esketamine on Days 4, 8, 11, 15, 18, 22 and 25.

    Drug: Placebo (Intranasal) · Drug: Esketamine

Interventions

  • DrugPlacebo (Intranasal)

    Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.

  • Participants will receive intranasal esketamine in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.

  • OtherAlcohol

    Participants will receive oral alcohol in Part A (as per the treatment sequence in period 1,2 and 3).

  • DrugPlacebo (Oral)

    Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3).

06

What researchers measure

Primary outcomes

  1. The Effect of a Single 84-Milligram (mg) Dose of Intranasal Esketamine Compared to Placebo, on Next day Driving Performance and Repeated Administration of 84 mg Intranasal Esketamine on Same-day Driving Performance

    Driving performance will be assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test.

    Time frame: Part A: Day 2

  2. The Effect of a Single 84-mg Dose of Intranasal Esketamine Compared to Placebo, on Next day Driving Performance and Repeated Administration of 84 mg Intranasal Esketamine on Same-day Driving Performance

    Driving performance will be assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test.

    Time frame: Part B: Day 1

  3. The Effect of a Single 84-mg Dose of Intranasal Esketamine Compared to Placebo, on Next day Driving Performance and Repeated Administration of 84 mg Intranasal Esketamine on Same-day Driving Performance

    Driving performance will be assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test.

    Time frame: Part B: Day 11

  4. The Effect of a Single 84-mg Dose of Intranasal Esketamine Compared to Placebo, on Next day Driving Performance and Repeated Administration of 84 mg Intranasal Esketamine on Same-day Driving Performance

    Driving performance will be assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test.

    Time frame: Part B: Day 18

  5. The Effect of a Single 84-mg Dose of Intranasal Esketamine Compared to Placebo, on Next day Driving Performance and Repeated Administration of 84 mg Intranasal Esketamine on Same-day Driving Performance

    Driving performance will be assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test.

    Time frame: Part B: Day 25

Secondary outcomes

  1. Effect on Subjective Driving Ability Scale

    Immediately after each driving test, subjects will indicate the perceived quality of their driving performance on a visual analog scale from 0 ('I drove exceptionally poorly') to 20 ('I drove exceptionally well') around a midpoint of 'I drove normally'.

    Time frame: Part A: Day 2; Part B: Day 1, 11, 18 and 25

  2. Karolinska Sleepiness Scale (KSS) Score

    KSS is a participant reported assessment used to rate sleepiness on a scale of 1 to 9, ranging from 'extremely alert' (1) to 'very sleepy, great effort to keep awake, fighting sleep (9).

    Time frame: Part A: Day 2; Part B: Day 1, 11, 18 and 25

  3. Efficacy Measured by the Montgomery Asberg Depression Rating Scale (MADRS)

    MADRS consists of 10 items covering all the important complaints which Participant with depression have (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts). Item is scored from 0 (normal) to 6 (severe). Total score (0 to 60) is calculated by adding the scores of all 10 items. A higher score represents a more severe condition. Negative Change in Score Indicates Improvement.

    Time frame: Baseline; Part A: Predose, Day 2; Part B: Predose, Days 1, 11, 18, and 25; End of study (up to Day 98)

  4. Effects on Suicidal Ideation/Behavior Measured by the Columbia Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a clinician rated assessment of suicidal behavior and / or intent. Scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.

    Time frame: Baseline; Part A: Predose, Day 2; Part B: Predose, Days 1, 11, 18, and 25; End of study (up to Day 98)

  5. Effects on Dissociative Symptoms Using the Clinician-Administered Dissociative State Scale (CADSS)

    The CADSS is an instrument for the measurement of present-state dissociative symptoms. The CADSS comprises 23 subjective items, divided into 3 components: Depersonalization, Derealization and Amnesia. Participant's responses are coded on a 5-point scale (0 = "Not at all" through to 4 = "Extremely").

    Time frame: Baseline; Part A: Predose, Day 1; Part B: Predose, Days 1, 11, 18, and 25

  6. Potential Relationship Between Changes in SDLP and the Plasma Concentration of Esketamine and Noresketamine

    Potential relationship will be assessed using visual displays of data. The relationship between the standard deviation of lateral position (SDLP) and the concentration of esketamine and noresketamine in plasma will be evaluated.

    Time frame: Part A: 1 hour postdose (Day 1); Part B: 1 hour postdose (Day 11, 18 and 25)

  7. Effect on Subjective Mental Effort Scale

    The level of mental effort the participant had to invest in performing the driving test will be assessed on a 15 centimeter (cm) visual analogue scale with markings ranging from 'absolutely no effort' to over 'extreme effort.

    Time frame: Part A: Day 2; Part B: Day 1, 11, 18 and 25

  8. Potential Relationship Between Changes in Mean Lateral Position (MLP) and the Plasma Concentration of Esketamine and Noresketamine

    Potential relationship will be assessed using visual displays of data. The relationship between the MLP and the concentration of esketamine and noresketamine in plasma will be evaluated. The MLP will be measured from a validated on-road driving test in a 100 kilometer (km) highway-driving lane.

    Time frame: Part A: 1 hour postdose (Day 1); Part B: 1 hour postdose (Day 11, 18 and 25)

  9. Potential Relationship Between Changes in Mean Speed and the Plasma Concentration of Esketamine and Noresketamine

    Potential relationship will be assessed using visual displays of data. The relationship between the mean speed (MS) and the concentration of esketamine and noresketamine in plasma will be evaluated. The MS will be measured from a validated on-road driving test in a 100 km highway-driving lane.

    Time frame: Part A: 1 hour postdose (Day 1); Part B: 1 hour postdose (Day 11, 18 and 25)

07

Study locations

1 site
  • Leiden, Netherlands
08

References and documents

Publications

  • Dijkstra FM, van de Loo AJ, Abdulahad S, Bosma ER, Hartog M, Huls H, Kuijper DC, de Vries E, Solanki B, Singh J, Aluisio L, Zannikos P, Stuurman FE, Jacobs GE, Verster JC. The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder. J Psychopharmacol. 2022 May;36(5):614-625. doi: 10.1177/02698811221078764. Epub 2022 Feb 25. PubMed 35212235 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Jun 2018, 20 months.

Of 40 industry-sponsored phase 1 interventional studies under Depressive Disorder, Major, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 12. This study's 20 months is above that.

Counting every sponsor, half of 88 studies reached it within 16 months; a quarter within 5 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2016
First posted
Sep 29, 2016
StartActual
Oct 7, 2016
Primary completionActual
Jun 29, 2018
CompletionActual
Jun 29, 2018
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02919579
Responsible party
Sponsor
First posted
Sep 29, 2016
Start date
Oct 7, 2016
Primary completion
Jun 29, 2018
Completion
Jun 29, 2018
Last update
Apr 27, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion